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Abstract Deletion of the long arm of chromosome 5, del(5q),
is the most prevalent cytogenetic abnormality in patients with
myelodysplastic syndromes (MDS). In isolation, it is tradition-
ally associated with favorable prognosis compared with other
subtypes of MDS. However, owing to the inherent heterogene-
ity of the disease, prognosis for patients with del(5q) MDS is
highly variable depending on the presence of factors such as
additional chromosomal abnormalities, >5 % blasts in the bone
marrow (BM), or transfusion dependence. Over recent years,
the immunomodulatory drug lenalidomide has demonstrated
remarkable efficacy in patients with del(5q) MDS. Advances in
the understanding of the pathogenesis of the disease have
suggested that lenalidomide targets aberrant signaling pathways
caused by haplosufficiency of specific genes in a commonly
deleted region on chromosome 5 (e.g., SPARC, RPS14,
Cdc25C, and PP2A). As a result, the agent specifically targets
del(5q) clones while also promoting erythropoiesis and
repopulation of the bone marrow in normal cells. This review
discusses recent developments in the understanding of the
mechanism of action of lenalidomide, and how this underlies
favorable outcomes in patients with del(5q) MDS. In addition,
we discuss how improved understanding of the mechanism of
disease will facilitate clinicians’ ability to predict/monitor re-
sponse and identify patients at risk of relapse.
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Introduction
Myelodysplastic syndromes (MDS) constitute a heteroge-
neous group of clonal hematopoietic disorders characterized
by bonemarrow (BM) failure, dysplasia, and an increased risk
of developing acute myeloid leukemia (AML) [1]. About
50 % of cases of MDS are characterized by the presence of
cytogenetic abnormalities in the BM [2]. The most prevalent
cytogenetic abnormality is a partial deletion of the long arm of
chromosome 5, del(5q), which is present in about 15 % of
cases [2]. It is becoming increasingly evident that del(5q)
MDS is a highly heterogeneous disease, and prognosis varies
widely depending on other factors such as presence of addi-
tional chromosomal abnormalities, >5% blasts in the BM, and
transfusion requirement [3, 4]. Therefore, it is important that
multiple risk factors are considered when deciding upon opti-
mal management strategies for patients with del(5q) MDS.
Most patients with del(5q) MDS become red blood cell
transfusion-dependent (RBC-TD) over the course of the dis-
ease. This has a major negative impact on survival, disease-
related morbidity, and quality of life [5–7]. Therefore, a major
goal of the clinical management of del(5q) MDS is to help
patients become red blood cell transfusion independent (RBC-
TI); this is complicated by the fact that patients with del(5q)
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MDS tend to respond poorly to erythropoiesis-stimulating
agents [8]. However, over the past decade, clinical trials have
demonstrated that patients with del(5q) MDS respond very
well to lenalidomide, an oral antineoplastic and immunomod-
ulatory agent [9–11]. Lenalidomide has direct effects on the
del(5q) clone as well as pleiotropic effects on erythropoiesis
and BM function, though the molecular basis of these phe-
nomena is only just beginning to be unravelled. As such, it is
important that themechanism of action (MoA) of lenalidomide
is fully delineated in order to understand why some patients are
refractory, or become resistant, to its effects. Furthermore,
precise tools are required to predict loss of response, or disease
progression, in patients treated with lenalidomide.
In this review, we discuss how the clinical activity and
tolerability profile of lenalidomide are linked to its MoA at
the cellular and molecular level. We also discuss how emerg-
ing insights into the “natural history” of del(5q) MDS neces-
sitate routine monitoring during lenalidomide therapy in order
to identify early signs of disease progression.
An overview of the pathogenesis of del(5q) MDS
By comparing overlapping chromosome 5 deletions among
patients with del(5q) MDS, two commonly deleted regions
(CDRs) have been identified. Horrigan et al. identified a 1–1.5
megabase region at chromosome 5q31 that was consistently
deleted in a cohort of patients with del(5q) MDS or AML (not
including patients with “5q– syndrome”—a subclass of dis-
ease characterized by <5 % BM blasts and specific morphol-
ogy and blood counts) [12]. This is known as the proximal
CDR and contains tumor suppressor genes associated with
advanced MDS. Similarly, Boultwood et al. identified a 1.5-
Mb region at 5q32–33 (the distal CDR) that underlies the
characteristic “5q– syndrome” phenotype [13]. Owing to the
proximity of the two CDRs, many patients with del(5q) MDS
have interstitial deletions that overlap both regions [14], and
this at least partially explains why most patients with del(5q)
MDS have a more severe disease phenotype, and poorer
prognosis, than that associated with “5q– syndrome.” Indeed,
in a recent study of patients with del(5q) MDS that utilized
single nucleotide polymorphismmicroarrays, Jerez et al. dem-
onstrated that severity of disease largely correlated with the
size of the 5q deletion [15].
Over the past decade, intensive analysis of the CDRs has
been undertaken to try to identify the pathogenetic determinants
of del(5q) MDS. Boultwood et al. systematically sequenced 40
genes within the distal CDR [16]. Despite exhaustive efforts, no
mutations were detected in these genes, suggesting that quali-
tative changes in, or complete loss of, gene expression are
unlikely to underlie the“5q– syndrome” phenotype. Converse-
ly, gene expression analysis in hematopoietic stem cells
(CD34+ cells) indicated that most genes within the distal
CDR were downregulated in patients with “5q– syndrome,”
suggesting that haploinsufficiency (reduced expression to a
level that does not support a wild-type phenotype, caused by
the presence of only one copy of a gene rather than two) could
at least partially explain the disease phenotype [16].
As discussed below, emerging data indicate that haplo-
insufficiency of distinct genes underlie different characteristic
features of the “5q– syndrome” including hypoplastic anemia,
megakaryocytic abnormalities, and clonal dominance of
del(5q) cells in the BM (Fig. 1). Notably, other chromosome
5q genes outside of the distal CDR seem to underlie the
heterogeneity of del(5q) MDS in terms of prognosis and
clinical outcomes [17].
The molecular basis for impaired erythropoiesis in del(5q)
MDS: haploinsufficiency of RPS14 and elevated p53
signaling
The ribosomal subunit 14 gene (RPS14), located within the
distal CDR, is essential for the assembly of ribosomal com-
plexes that translate mRNA into proteins. Several lines of
direct and indirect evidence strongly implicate RPS14 in the
pathogenesis of del(5q) MDS: (1) inactivating mutations of
other ribosomal proteins have been linked with congenital BM
failure syndromes such as Diamond–Blackfan anemia [18];
(2) systematic experimental knockdown of CDR genes in
normal human CD34+ cells by RNA interference (RNAi)
indicated that only the knockdown of RPS14 suppressed
erythroblast proliferation and viability, without a significant
impact on thrombopoiesis [19]; (3) forced expression of
RPS14 in CD34+ cells from patients with del(5q) MDS re-
stored normal erythropoiesis [19];(4) haploinsufficiency of the
RPS14 region in a mouse model led to a “5q– syndrome”
MDS-like phenotype with macrocytic anemia and mono-
lobulated megakaryocytes; [20] however, these mice did not
demonstrate thrombocytosis or neutropenia, suggesting the
involvement of distinct haploinsufficient genes in the myeloid
and megakaryocyte abnormalities that are characteristic of
del(5q) MDS. Experimental evidence indicates that haplo-
insufficiency of RPS14 upregulates the p53 pathway, a key
pathway that induces cell cycle arrest and apoptosis, specifi-
cally in erythroid cells, leading to hypoplastic anemia [17, 21].
Dutt et al. demonstrated that RNAi downregulation of RPS14
led to an accumulation of p53 in erythroid progenitor cells, but
not myeloid cells or megakaryoctes, leading to apoptosis [21].
Pharmacological inhibition of p53 blocked apoptosis in these
cells [21]. Furthermore, in a series of intricate in vivo exper-
iments involving the cross breeding of RPS14 haploin-
sufficient mice with p53 knockout mice, Barlow et al. dem-
onstrated that absence of p53 completely blocked the devel-
opment of a “5q–syndrome”MDS-like phenotype [20]. There
is also evidence that the p53 pathway plays a key role in the
development of del(5q) MDS in patients; gene expression
analysis of CD34+ cells indicated that several genes in the
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p53 pathway are upregulated in patients with del(5q) MDS
compared with healthy controls [22].
Progress has been made in understanding the molecular
mechanism by which RPS14 haploinsufficiency leads to an
accumulation of p53 in del(5q) erythroid progenitors [21]. It
is thought that reduced expression of RPS14 interferes with
normal ribosomal biosynthesis and leads to high levels of free
ribosomal proteins in the cell. Free ribosomal proteins block the
binding of human homolog of murine double minute 2
(MDM2) to p53, thereby preventing ubiquitination and degra-
dation [23]. Consequently, p53 accumulates in erythroid pro-
genitor cells and drives apoptosis [23]. Interestingly, the prox-
imal CDR includes two genes that are complementary
coregulators of MDM2 and the cell cycle, the protein phospha-
tase 2a (PP2A) gene and the cell division cycle 25 C (CDC25C)
gene. PP2A inactivates MDM2 by dephosphorylating it; in its
inactive state, MDM2 cannot bind and inactivate p53 [24].
CDC25C is a phosphatase that positively regulates the G2-M
checkpoint in the cell cycle and is also regulated by the activity
of PP2A [25]. It follows, therefore, that MDM2, PP2A, and
CDC25C constitute therapeutic targets for the correction of
defective erythropoiesis in patients with del(5q) MDS.
The molecular basis for thrombocytosis and neutropenia
in del(5q) MDS: haploinsufficiency of microRNA genes
Two important microRNA (miRNA) genes, miRNA-145 and -
146a, are located within or close to the distal CDR. These
encode RNA sequences that downregulate genes involved in
the regulation of the innate immune system. Both genes are
downregulated in CD34+ cells from patients with del(5q)MDS
compared with CD34+ cells from patients with non-del(5q)
MDS and healthy controls [26]. To assess the biological con-
sequences of their reduced expression, Starczynowski et al.
stably knocked down miRNA-145 and 146a in mouse
CD34+ cells, which were subsequently transplanted into mice
that had been myeloablated by irradiation, along with normal
stem/progenitor cells to mimic BM mosaicism [26]. After
8 weeks, mice exhibited variable neutropenia, hypolobulated
megakaryocytes, and suppressed myeloid progenitor activity in
the BM. A similar phenotype was observed in irradiated mice
transplanted with CD34+ cells with forced overexpression of
TNF receptor-associated factor-6 (TRAF-6), a downstream
target of miRNA-146a [26]. The phenotype was dependent
on IL-6 (a pro-inflammatory cytokine); a near normal pheno-
type was observed when irradiated mice were transplanted with
CD34+ cells derived from IL-6-deficient mice that were ma-
nipulated to overexpress TRAF-6 [26]. Interestingly, these
mouse models mimicked the natural progression of del(5q)
MDS with approximately a third of mice developing BM
failure or AML. Disease progression was associated with clonal
dominance; mice that progressed had much higher levels of the
manipulated clone in the BM than mice that did not progress.
The molecular basis for clonal dominance of del(5q)
progenitors: haploinsufficiency of tumor suppressor genes
Del(5q) MDS is characterized by its clonal nature. In most
patients, >99 % of CD34+ cells carry the del(5q) abnormality
and the BM is generally hypercellular or normocellular [27,
28]. Clearly, therefore, the presence of a del(5q) aberration
exerts a proliferative advantage.
Several haploinsufficient genes may contribute to the
proliferative advantage of del(5q) clones (Fig. 1). Specific
genes that may be involved include: EGR1, a zinc finger
transcription factor gene that regulates the expression of
several known tumor suppressor genes (e.g., TP53,
CDKN1A/p21, TGFB, and PTEN) and reduces prolifera-
tion [29]; APC, a negative regulator of beta catenin function
which itself is closely involved in stem cell self-renewal
and hematologic malignancy [30, 31]; and SPARC, a tumor
suppressor gene that regulates extracellular interactions and
is known to have anti-angiogenic, antiproliferative, and
anti-adhesive properties [32].
IFig. 1 Genes in the commonly
deleted region of chromosome 5q
that are implicated in the
pathogenesis of del(5q) MDS [19,
20, 25, 26, 66–68]. del(5q)
deletion of the long arm of
chromosome 5, MDS
myelodysplastic syndromes
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In addition, mice that are haploinsufficient for DIAPH1
display myelodysplastic features with hypercellular bone mar-
row [33]. DIAPH1 is located just outside the CDR, has been
shown to regulate the dynamics of the actin cytoskeleton,
which is essential for the coordination of cell division and
other cellular processes. Another notable gene candidate that
is likely to be involved in del(5q) clonal dominance is NPM-1,
a tumor suppressor gene that is frequently mutated in patients
with AML and high-risk MDS [34].
The molecular basis for heterogeneity of del(5q) MDS:
molecular defects outside of chromosome 5q
Despite common pathophysiological features due to
haploinsufficiency of chromosome 5q, del(5q) MDS is actu-
ally a highly heterogeneous disease with variable prognosis.
Several retrospective analyses of patients with del(5q) MDS
have shown that the existence of additional karyotypic abnor-
malities is strongly associated with poorer overall survival
(OS) and greater risk of progression to AML [3, 35]. In the
largest study to date, in 541 patients with del(5q) MDS, Mallo
et al. demonstrated that OS was significantly reduced in
patients with ≥2 additional karyotypic abnormalities vs pa-
tients with ≤1 additional karyotypic abnormality [3]. Further-
more, the presence of any additional karyotypic abnormality
increased the risk of progression to AML compared with
isolated del(5q) MDS. The most common single additional
aberrations observed were del(12p), trisomy 21, trisomy 8 and
del(20q). These observations highlight the importance of full
karyotypic analysis for patients with suspected del(5q) MDS,
both in terms of accurate prognostication and selection of
appropriate treatment strategy.
In addition to karyotypic abnormalities, the existence of
certain point mutations can also have a profound impact on
prognosis in patients with del(5q) MDS. Notably, mutations in
TP53 (the gene that encodes p53) are frequently observed in
patients with complex karyotypes involving del(5q) [36–38]. It
has long been recognized that the presence of TP53 mutations
has a negative impact on prognosis that is independent of
International Prognostic Scoring System (IPSS) score [39].
Moreover, recent technological advances have facilitated the
screening of patients for TP53 mutations. By using next-
generation sequencing, a technique that can detect mutations
present in a small proportion of cells, Jadersten et al. detected
TP53 mutations in ∼20 % of patients with lower-risk del(5q)
MDS, although notably, the majority of patients did not have a
complex karyotype. The presence of TP53 mutations predicted
progression to AML and the proportion of cells carrying mu-
tations increased with disease progression [40]. As TP53 mu-
tations were generally detectable at an early stage of disease, the
authors concluded that TP53 should be routinely analyzed,
either by immunohistochemistry or next-generation sequencing
during initial patient assessments [40]. Indeed, as the molecular
pathogenesis of MDS is further dissected and emerging geno-
mic technologies such as next-generation sequencing and gene
expression microarrays becomemore accessible, it is likely that
they will become increasingly important in assessing prognosis
in patients with del(5q) MDS.
Other prognostic indicators that must be taken into consid-
eration include bone marrow blast count ≥5 % [3],
dysgranulopoiesis [4], transfusion need at presentation [4],
and platelet count [3]. Another factor that confers poor prog-
nosis in patients with del(5q)MDS is a BMblast count of ≥5%.
The World Health Organization (WHO) definition of del(5q)
MDS specifies a blast count of <5 % [41]. However, ∼40 % of
patients with del(5q) MDS have a higher blast count than this
[3]. Multivariate analysis has indicated that a blast count of
≥5 % is associated with poor survival and increased risk of
progression to AML [3]. It is essential, therefore, that BM
biopsies are taken from patients with del(5q) MDS in order to
allow an accurate diagnosis and prognosis.
Molecular and cellular mechanisms of sensitivity
to lenalidomide in del(5q) MDS patients
Early clinical trial data demonstrated that patients with del(5q)
MDSwere particularly sensitive to lenalidomide; in theMDS-
001 trial, a phase I–II trial of lenalidomide in 43 patients with
both del(5q) and non-del(5q) MDS, 10/12 (83 %) patients
with a del(5q) aberration achieved an erythroid response com-
pared with 13/23 (57 %) patients with a normal karyotype and
1/8 (12 %) patients with other cytogenetic abnormalities [10].
Erythroid responses were also high in subsequent trials; 67 %
of del(5q) MDS patients treated with lenalidomide became
RBC-TI in the single-arm phase II MDS-003 study; in the
placebo-controlled phase III MDS-004 study 56 % of patients
who received lenalidomide 10 mg became RBC-TI [9, 11].
In support of these results, emerging data have provided
insights into why lenalidomide displays such remarkable ef-
ficacy in patients with del(5q) MDS.
Evidence that lenalidomide directly targets the del(5q) clone
The sensitivity of del(5q) MDS cells to lenalidomide has been
demonstrated in vitro. Pellagatti et al. isolated del(5q) and
normal CD34+ cells from patients with del(5q) MDS and
cultured them in the presence or absence of lenalidomide.
After 14 days, lenalidomide inhibited del(5q) cell growth but
had no effect on the growth of normal cells [32]. In a separate
study, Wei et al. demonstrated that lenalidomide induced a
concentration-dependent increase in apoptosis in del(5q)
CD34+ cells isolated from patients with AML that evolved
from MDS. In contrast, lenalidomide had no effect on apo-
ptosis in CD34+ cells with a normal karyotype [25]. The
sensitivity of del(5q) cells to lenalidomide has also been
demonstrated in vivo. As part of the MDS-001 trial, List
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et al. analyzed trephine BM biopsy specimens from 18 pa-
tients for changes in BM microvessel density and apoptotic
index following treatment with lenalidomide. Patients with
del(5q) MDS who achieved a major erythroid response
displayed increased apoptosis and reduced microvessel den-
sity compared with patients who did not respond [42]. In a
study by Tehranchi et al., the cytogenetics of hematologic
stem and progenitor cell populations in eight RBC-TD del(5q)
MDS patients was evaluated, before and during treatment with
lenalidomide [43]. All seven patients that became transfusion-
independent during treatment showed cytogenetic responses
by conventional cytogenetics, and a dramatic reduction in the
proportion of CD34+/CD38+ progenitor cells with the 5q
deletion. Notably, in three patients, no CD34+/CD38+ pro-
genitors with the 5q deletion were identified at remission. In
contrast, the one patient who did not become transfusion-
independent did not achieve a cytogenetic response in either
the hematologic stem cell or progenitor cell populations.
Together, these findings strongly suggest that lenalidomide
is particularly cytotoxic to del(5q) progenitor cells, while
having negligible effects on normal progenitors.
Although lenalidomide can target and reduce del(5q)
clones, it is not a curative treatment; approximately 50 % of
patients have clinical and cytogenetic relapse within 2–3 years
of treatment [10, 11]. The Tehranchi et al. study demonstrated
that although the majority of del(5q) clones are removed from
the BM progenitor compartment, some lenalidomide-resistant
del(5q) cells may persist in the stem cell compartment due to
their quiescent state and/or high expression of multidrug re-
sistance genes [43]. In patients who relapse, it is thought that
these resistant stem cells expand to populate the progenitor
compartment. The precise molecular mechanism(s) underly-
ing acquired resistance to lenalidomide has not been fully
elucidated, but seems to be associated with the acquisition of
additional cytogenetic aberrations in re-emergent del(5q)
clones (clonal evolution) [43]. It is very important, therefore,
to monitor cytogenetic response in patients treated with
lenalidomide in order to detect early evidence of disease
progression [44]. At the moment, it is recommended that
follow-up karyotyping should be undertaken by standard
metaphase cytogenetics [44]. However, emerging techniques,
such as fluorescence in situ hybridization on CD34+ periph-
eral blood cells [45], may provide supplementary and more
convenient approaches for monitoring of patients in the future.
Impact of lenalidomide on haploinsufficient genes
and their pathways in the del(5q) clone
As discussed above, a key effector of hypoplastic anemia in
patients with del(5q) MDS is thought to be impaired ribosome
biosynthesis that leads to p53-mediated apoptosis of erythroid
cells carrying the del(5q) aberration. Central to this phenomenon
is the p53 downregulator, MDM2, whose degradation is
triggered by free ribosomal proteins [24]. Recent data have
demonstrated that lenalidomide stabilizes MDM2, thereby ac-
celerating p53 degradation. Themolecular basis of this phenom-
enon has been elucidated based on an elaborate series of exper-
iments undertaken by Wei et al. In an in vitro assay, it was
demonstrated that lenalidomide dose-dependently inhibited
CDC25C and PP2A which, in turn, suppressed MDM2 auto-
ubiquitinylation and subsequent degradation [25]. Further ex-
periments demonstrated that the haploinsufficiency of CDC25C
and PP2A in del(5q) cells is important to confer sensitivity to
lenalidomide. In cultured non-del(5q) BM cells, lenalidomide
induced statistically significant apoptotic activity. However,
when CDC25C or PP2A expression was reduced by RNAi
(mimicking their haploinsufficiency) lenalidomide had a greater
apoptotic effect [25]. Therefore, reduced expression of key
negative regulators of MDM2 in del(5q) MDS cells leads to
increased sensitivity to lenalidomide.
As well as mediating sensitivity to lenalidomide in del(5q)
cells, experimental evidence suggests that PP2A and CDC25C
are integral to acquired resistance to lenalidomide therapy. For
instance, forced overexpression of PP2A in cells promotes drug
resistance [24]. Moreover, sequential BM specimens from pa-
tients who become resistant to lenalidomide indicate that resis-
tance coincides with overexpression of PP2A and restored
accumulation of p53 in erythroid precursors [24].
Experiments in primary del(5q) CD34+ cells have demon-
strated that lenalidomide can also upregulate haploinsufficient
miRNAs implicated in the pathogenesis of the disease, such as
miRNA-143 and miRNA-145 [46] Venner et al. examined the
effect of lenalidomide on pre-treatment CD34+ cells from ten
patients with del(5q) MDS. Statistically significant increases in
miRNA-143 (1.8-fold; P=0.02) and miRNA-145 (1.9-fold;
P=0.01) expression were observed in del(5q) cells compared
with wild-type CD34+ cells; changes in expression correlated
with sensitivity to lenalidomide [46]. Furthermore, RNAi knock-
down of miRNA-143 and miRNA-145 in healthy cord blood
CD34+ cells (thus mimicking haploinsufficiency) conferred
sensitivity to lenalidomide. These data suggest that the sensitiv-
ity of del(5q) cells to lenalidomide is at least partially explained
by normalization of expression of haploinsufficient miRNAs.
Lenalidomide also appears to normalize the expression of
SPARC. Pellagati et al. assessed global gene expression in
CD34+ cells isolated from patients with del(5q) MDS that
were cultured for 5 days with or without lenalidomide [32].
After incubation with lenalidomide, 98 % of cells were still
del(5q) positive; therefore, any changes in mRNA levels were
likely to reflect a direct effect of lenalidomide on gene expres-
sion, rather than an indirect effect due to clonal suppression of
del(5q) cells. Out of the 41 genes within the distal CDR that
were analyzed, only SPARCwas upregulated by lenalidomide
(demonstrating a fourfold increase in expression), although a
number of genes outside the CDR were also upregulated,
including several genes involved in extracellular matrix
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interactions. Venner et al. also observed an increase in SPARC
mRNA levels when CD34+ cells from ten del(5q) MDS pa-
tients were treated ex vivo with lenalidomide [46]. These
observations suggest that lenalidomide may normalize SPARC
expression in patients with del(5q) MDS [46]; increased
SPARC would reduce cell–cell adhesion and proliferation of
del(5q) clones by normalizing extracellular matrix interactions.
Collectively, these studies demonstrate that lenalidomide
can effectively reduce del(5q) progenitors in the BM by
specifically targeting haploinsufficient genes and their path-
ways (Fig. 2). This MoA is reflected in the high rates of
cytogenetic response (50–83 %) in patients with del(5q)
MDS treated with lenalidomide [9–11].
Impact of lenalidomide on erythropoiesis and BM function
in patients with del(5q) MDS
Clinical data have demonstrated that lenalidomide often has a
potent myeloablative effect during the early stages of treatment
which coincides with the effective elimination of del(5q) clonal
myeloid progenitors [9]. Consequently, cytopenic adverse events
(AEs) are to be expected in patients during early cycles (discussed
below). Following reduction of the del(5q) clone, it is thought that
a small pre-existing pool of normal hematopoietic stem cells
repopulate the myeloid and erythroid progenitor compartments
[43]. Along with reducing the del(5q) clone, there is evidence to
suggest that lenalidomide can accelerate this repopulation process
owing to a range of beneficial effects on BM function.
In a recent study, Ximeri et al. collected BM cells from ten
patients with del(5q) MDS before and after treatment with
lenalidomide and assessed changes in erythropoiesis and
clonogenic potential [47]. Purified CD34+ cells, early ery-
throid precursors, and mature erythroid precursors were sorted
and quantified by flow cytometric analysis. Unsurprisingly,
the percentage of CD34+ cells in the total progenitor popula-
tion was significantly decreased following lenalidomide treat-
ment, reflecting specific targeting of del(5q) progenitor cells.
In contrast, the percentage of early and mature precursors was
significantly increased following lenalidomide treatment; the-
se normal cells were less resistant to apoptosis than del(5q)
cells. Lenalidomide improved the clonogenic potential of
normal BM progenitor cells in erythroid, myeloid, and mega-
karyocytic lineages. In a different study of cultured non-
del(5q) CD34+ cells, lenalidomide induced expression of a
number of genes known to promote erythroid differentiation
including IL1R2, FLT3, and CD163 [48]. These studies sug-
gest that lenalidomide not only selectively destroys del(5q)
cells but also promotes repopulation of the BM with normal
erythroid precursors. Moreover, lenalidomide seems to correct
hypercellularity of the BM by restoring normal apoptotic
potential of erythroid precursor cells [47].
Lenalidomide also seems to improve the hematopoiesis-
supporting capacity of BM stroma. Ximeri et al. assessed the
impact of lenalidomide on the BM microenviroment in long-
term cultures of BM cells (LTBMCs) isolated from patients
with del(5q)MDS treated with lenalidomide [47]. LTBMCs are
an established in vitro model of BM function which involves
growing hematopoietic and mesenchymal-derived cells in
layers; clonogenicity of the LTBMCs is reflected by the number
of colony-forming cells (CFCs) released into the media. In this
study, the number of CFCs in the media was significantly
greater in LTBMCs from lenalidomide-treated patients than
untreated patients [47]. Improved BM function was reflected
by an increase in the adhesive properties of CD34+ cells and
stromal cells. Lenalidomide increased cell surface expression of
adhesion molecules on CD34+ cells including CD11a, CD48,
and CxCR4; lenalidomide also increased release of pro-
adhesive cytokines from stromal cells in LTBMCs including
I I IFig. 2 The effect of lenalidomide
on haploinsufficient genes and
their pathways in del(5q) clones
[25, 29, 32, 69–71] del(5q)
deletion of the long arm of
chromosome 5
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ICAM-1 and SDF-1α (the natural ligands for CD11a and
CXCR4, respectively).
Impact of lenalidomide on immune function and angiogenesis
in patients with del(5q) MDS
In many cancers, including myeloid malignancies, impaired
immune function is thought to contribute to disease progression
by allowing tumor cells to evade the immune system [49].
Specific immune abnormalities implicated in the pathogenesis
of MDS include defective synapse interactions between
antigen-presenting cells and T cells, diminished natural killer
cell activity, and alteration of cytokines in the BM microenvi-
ronment [49].
Experimental evidence suggests that lenalidomide corrects
immune defects in patients withMDS. For example, in cultured
CD34+ cells from patients with del(5q) MDS, treatment with
lenalidomide increased the proportion of activated peripheral
blood T cells compared with untreated cells [47]. Furthermore,
although not specifically assessed in MDS, lenalidomide can
correct defective synapse interactions between antigen-
presenting cells and T cells in chronic lymphocytic leukemia
cells by modifying T cell actin dynamics [50]. Lenalidomide
also reduces the expression of proinflammatory cytokines (e.g.,
TNF-α, IL-1β, and IL-6) and increases anti-inflammatory cy-
tokines (e.g., IL-10) in peripheral bloodmononuclear cells [51].
These observations are of interest because IL-6, in particular, is
a key effector of dysregulated innate immune pathways in
del(5q) MDS, due to haploinsufficiency of miRNA-145 and
miRNA-146a [26].
Angiogenesis also plays an important role in the pro-
gression of hematopoietic malignancies. Lenalidomide is
known to have an anti-angiogenic effect in patients with
del(5q) MDS [52–55]. Reduced BM vascularity in del(5q)
MDS patients treated with lenalidomide correlated with
clinical response and reduced risk of disease progression
[42]. Loss of the anti-angiogenic effect predicted disease
progression.
Linking the mechanism of action of lenalidomide to observed
clinical outcomes
Clinical experience with lenalidomide in del(5q) MDS has
recently been reviewed in detail elsewhere [14, 56]. In this
section, we briefly discuss key clinical findings from the
MDS-003 and MDS-004 trials in the context of recent devel-
opments in the understanding of theMoA of lenalidomide and
suggest a model linking its molecular and cellular actions with
clinical outcomes (Fig. 3). MDS-003 was a single-arm phase
II study and MDS-004 was a placebo-controlled phase III
study. Both trials assessed the safety and efficacy of
lenalidomide in patients with lower-risk RBC-TD del(5q)
MDS [9, 11].
Erythroid and cytogenetic responses in patients with del(5q)
MDS treated with lenalidomide
In clinical trials, treatment with lenalidomide has been associ-
ated with high erythroid response rates in patients with RBC-
TD del(5q) MDS. In MDS-003 (N=148), 67 % of patients
became RBC-TI by week 24 of treatment [11]. In MDS-004
(N=205), 56 % of the 41 patients who initially received 10 mg/
day of lenalidomide became RBC-TI for ≥26 weeks [9]. The
observed high response rates in patients with del(5q) MDS are
of major clinical relevance because chronic anemia impacts
quality of life (QoL) and is associated with hypertrophic cardiac
remodeling over time [11]. Moreover, anemia and RBC-TD are
both independently correlated with reduced survival [57]. Ery-
throid responses with lenalidomide tended to be durable; in
MDS-003, responses lasted for >1 year in 62% of patients [14],
in MDS-004, median duration of response had not been
reached after a median follow-up of 1.5 years [9]. Responses
were generally rapid, with median times to response of 4.6 and
4.1 weeks in MDS-003 and MDS-004, respectively. Erythroid
responses correlated with cytogenetic responses, which oc-
curred in 73 % of 85 patients in MDS-003 evaluable for
cytogenetic response and 50 % of 69 patients receiving
lenalidomide 10 mg in MDS-004 [9, 11]. Response to
lenalidomide in MDS-004 was also associated with clinically
meaningful improvements in health-related QoL [9].
The observed rapid and durable responses to lenalidomide in
patients with del(5q) MDS in clinical trials reflect: (1) direct
cytotoxicity against the del(5q) clone, leading to high cytogenetic
response rates; (2) the ability of lenalidomide to stimulate normal
erythropoiesis andBM function, leading to a repopulation of BM
with lineages derived from normal CD34+ cells.
Characteristic AE profile in patients with del(5q) MDS treated
with lenalidomide
In both MDS-003 andMDS-004, there was a high incidence of
cytopenias that occurred soon after initiation of lenalidomide
treatment. In MDS-003, moderate-to-severe thrombocytopenia
and neutropenia occurred in 44 and 55 % of patients, respec-
tively. Approximately two thirds of hematologic grade 3–4AEs
occurred in the first 8 weeks of treatment. Importantly, most
cases could be effectively managed with dose adjustments,
dose delays, and/or myeloid growth factors; 20 % of patients
discontinued lenalidomide due to AEs. In MDS-004, thrombo-
cytopenia and neutropenia occurred in 41 and 75 % of patients
treated with 10 mg lenalidomide, respectively. Dose reduction
was required in 58 % of patients, and discontinuation was
necessary in 9 % of patients. Apart from hematologic AEs,
lenalidomide was generally well tolerated.
The high incidence of early hematologic AEs likely reflects
rapid elimination of del(5q) progenitors, which disrupts hema-
topoiesis before the BM has a chance to recover and repopulate
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with normal progenitor cells and derived lineages. Indeed, the
development of early hematologic AEs seems to predict sub-
sequent clinical response, probably because they signify the
effective elimination of the oncogenic clone. For example, in
MDS-003, development of thrombocytopenia or neutropenia
correlated with attainment of RBC-TI [58]. Notably, patients
with del(5q) MDS have higher rates of cytopenias than non-
del(5q) patients, suggesting that effective clonal suppression
may be the predominant explanation for hematologic AEs
during early treatment cycles.
The impact of hematologic and cytogenetic responses
on survival and disease progression in patients with del(5q)
MDS treated with lenalidomide
Response to lenalidomide is associated with enduring im-
provements in survival and reduced risk of progression to
AML. In MDS-004, patients treated with lenalidomide who
achieved RBC-TI had significantly improved OS, and reduced
risk of progression to AML compared with patients who did
not respond [9]. There was no significant difference in OS or
progression to AML in patients treated with lenalidomide and
those originally assigned placebo; however, these observations
may be confounded by the fact that patients given placebo
could cross over to receive lenalidomide after 16 weeks. Fur-
thermore, in MDS-004, higher doses of lenalidomide were asso-
ciated with more hematologic and cytogenetic responses. RBC-
TI was achieved by 56.1, 42.6, and 5.9% of patients treated with
lenalidomide 10mg, 5mg, and placebo, respectively (P<0.001).
Cytogenetic response rates were 50.0 and 25.0 % in the
lenalidomide 10 and 5 mg cohorts, respectively (P=0.066). In
addition, median OS was 42.4, ≥35.5, and 44.5 months in the
placebo, lenalidomide 5 and 10 mg groups, respectively. After a
recent follow-up study, the 4-year OS rates were 50% in patients
treatedwith lenalidomide (10mg) and 44% in patients whowere
originally assigned to placebo but crossed over to lenalidomide
(median follow-up, 3.1 and 3.8 years, respectively) [59]. In
MDS-003, the predicted 10-year OS was 78 % for cytogenetic
responders and 4 % for non-responders; the predicted AML
progression rate in cytogenetic responders and non-responders
was 15 and 67 %, respectively [14].
The risk of AML progression in patients with del(5q) MDS
There has been some concern that patients with del(5q) MDS
who do not respond to lenalidomide treatment may have an
enhanced risk of progression to AML. Gohring et al. undertook




















Fig. 3 A model linking MoA of lenalidomide with clinical data. In
patients with del(5q) MDS, lenalidomide has a direct cytotoxic effect
on abnormal del(5q) clones, by targeting haploinsufficient genes and their
pathways. The high probability of cytogenetic remission in patients given
lenalidomide reflects this potent cytotoxic effect on del(5q) cells. Because
of the clonal nature of the disease, lenalidomide often has a myeloablative
effect during early cycles of treatment resulting in high frequencies of
cytopenic AEs [9, 11]. These AEs are transient and usually manageable
on-treatment by dose reductions, delays, or concomitant myeloid growth
factors. Once the del(5q) clone has effectively been eliminated, the BM is
repopulated with lineages derived from a small number of normal CD34+
that are not eliminated by lenalidomide. A rapid return to normal hema-
topoiesis is facilitated by pleiotropic beneficial effects of lenalidomide on
BM function [11, 47, 49]. The replacement of del(5q) precursors with
normal ones leads to high rates of durable RBC-TI, usually with 4–
5 weeks [9, 11]. Achievement of RBC-TI is associated with significant
benefits in terms of improved overall survival, reduced probability of
non-leukemic death, and improved QoL [9, 11]. Cytogenetic response is
associated with reduced progression to AML [14]. However, del(5q)
MDS is a heterogeneous disease, and some patients, including those
treated with lenalidomide, remain at risk of AML progression due to
clonal evolution [3, 4]. Therefore, patients must be carefully assessed for
their probability of disease progression prior to initiating treatment. Also,
regular monitoring of cytogenetic response in patients treated with
lenalidomide is essential [44].MoAmechanism of action, del(5q) deletion
of the long arm of chromosome 5,MDS myelodysplastic syndromes, AE
adverse event, BM bone marrow, RBC-TI red blood cell transfusion
independent, QoL quality of life, AML acute myeloid leukemia
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patients treated with lenalidomide [60]. A total of 36 % of
patients progressed to AML. Strikingly, 87 % of patients who
progressed acquired additional chromosomal aberrations. The
risk of progression was higher in patients who did not achieve a
cytogenetic response; cumulative incidence of AML after
5 years was 21 and 60 % in cytogenetic responders and non-
responders, respectively [60]. These observations further rein-
force the hypothesis that clonal evolution is the driving force of
leukemic transformation in patients with del(5q)MDS. Regular
cytogenetic assessment of patients treated with lenalidomide is
a prudent approach to monitor for clonal evolution [60].
Concerns about the possibility of leukemic progression with
lenalidomide have prompted studies of AMLprogression rates in
del(5q) MDS patients in general. For example, in a retrospective
multicenter analysis of 318 untreated lower-risk del(5q) MDS
patients from the Dusseldorf registry, Germing et al. reported that
12.6 % of patients progressed to AML, and cumulative progres-
sion rates at 2 and 5 years were 4.9 and 17.6%, respectively [61].
However, the risk of progression was very variable reflecting the
heterogeneity of the disease. Risk factors that were independently
associated with disease progression included blast count >5 %,
RBC-TD at diagnosis, and a WHO Prognostic Scoring System
score of intermediate, high, or very high. RBC-TD at diagnosis
was a particularly important parameter that indicated increased
risk of progression. Progression within the first 2 years was
mainly observed in RBC-TD patients; the risk of progression at
2 years was 11 and 2 % in RBC-TD and RBC-TI patients,
respectively. It seems, therefore, that some patients with del(5q)
MDS may be at high risk of AML progression, reflecting the
complexity of the biology of the disease.
As a result of this finding, several retrospective studies of
AML progression rates have been undertaken in treated vs
untreated patients. Ades et al. assessed AML progression rates
in 95 patients with RBC-TD del(5q) MDS treated with
lenalidomide [62]. Progression rates were compared with a
historical cohort of 99 patients who had never received
lenalidomide using a propensity score approach, a statistical
methodology that can compare treatment effects from indepen-
dent observational studies in an unbiased manner [63]. In this
study, the 4-year cumulative incidence of AML was 9.0 % in
the lenalidomide group and 15.8 % in the untreated group
(P=0.16). Median survival from diagnosis was 150 and
78 months in the two groups, respectively (P=0.06). Similar
results were reported in a separate analysis by Kuendgen et al.
[64]. In this study, del(5q) MDS patients treated with
lenalidomide in the MDS-003 and MDS-004 trials were com-
pared with del(5q) patients from the Dusseldorf MDS registry
who were never exposed to the drug, After a median follow-up
of 4.3 years (lenalidomide-treated patients) and 4.6 years
(untreated patients), there was no significant difference in 2-
year cumulative AML progression risk between the two groups
(6.9 vs 12.1 %, P=0.930). Conversely, treatment with lena-
lidomide was associated with improved survival; 2-year OS
probabilities were 89.9 and 74.4 %, respectively [64]. Based on
these data, lenalidomide does not appear to increase the risk of
progression to AML in patients with del(5q) MDS.
Emerging data indicate that AMLprogression rates in patients
treated with lenalidomide are not drug-related, but are associated
with additional risk factors [65]. In a combined analysis ofMDS-
003 and MDS-004, both transfusion burden and karyotype
complexity were associated with increased risk of AML progres-
sion. For instance, patients with del(5q) MDS and ≥2 additional
cytogenetic abnormalities were at increased risk of progression
to AML vs patients with isolated del(5q) MDS [65].
Summary and conclusions
In patients with del(5q) MDS, lenalidomide induces durable
hematologic responses through a direct cytotoxic effect to
abnormal del(5q) clones, by targeting haploinsufficient genes
and their pathways. The high probability of cytogenetic remis-
sion in patients given lenalidomide reflects this potent cytotoxic
effect on del(5q) cells. It also has pleiotropic effects on hema-
topoiesis and the BM microenvironment. Myelosuppression
during early treatment cycles should be expected with
lenalidomide, which reflects the time between elimination of
the del(5q) clone and repopulation of the BM with normal
precursors. Effective reduction of the del(5q) clone has a pos-
itive impact on clinical outcome; achievement of cytogenetic
response and RBC-TI are associated with reduced risk of AML
progression and improved survival. Del(5q) MDS is a highly
heterogeneous disease, and a number of additional risk factors
have been identified that predict disease progression. Patients
treated with lenalidomide should be routinely monitored, with
particular attention given to possible clonal evolution, so that
changes in treatment strategy may be considered prior to clin-
ical progression.
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